#China #Suzhou #Crystal Pharmatech #ELDICO ED-1 #MicroED Services

Crystal Pharmatech Unveils ELDICO ED-1: A New Era in Solid-State Research

Crystal Pharmatech, a prominent CRO/CDMO known for its science-based focus, has recently announced the successful installation of the ELDICO ED-1 electron diffractometer at its research and development (R&D) center located in Suzhou, China. This development marks a significant milestone as it stands as the first ELDICO ED-1 installed in the entire Asia-Pacific region, further strengthening the company's capabilities in solid-state research, preformulation studies, and formulation development for small-molecule pharmaceuticals.

Enhanced MicroED Capabilities

The ED-1 electron diffractometer is engineered to collect precise electron diffraction data from small-molecule crystals. Crystal Pharmatech has previously launched MicroED services using a cryo-electron microscope, but this new automated platform enables a more efficient and rapid analysis. With state-of-the-art features such as a horizontal beam path, a 5-axis goniometer, and a DECTRIS QUADRO hybrid pixel detector, the ED-1 is capable of providing timely and accurate structural determinations, significantly enhancing productivity.

In fact, the ED-1 was already operational within just three days of its installation, a testament to the seamless integration and expertise of Crystal Pharmatech’s team. The combination of the ED-1's automated calibration and data collection capabilities allows researchers to measure a variety of crystal forms with unprecedented speed, delivering results in as little as 48 hours under expedited services.

Cutting-Edge Research Applications

One of the standout features of Crystal Pharmatech's integration of the ED-1 is its unique positioning alongside the company's screening and crystallization teams. This proximity allows MicroED to become a routine part of the solid-form screening process, enhancing the efficiency of the development pipeline. Clients are now able to request detailed analyses of crystal structures derived from sub-micron powders, requiring minimal sample quantities of just 1 mg.

The ED-1 facilitates the identification of various forms, including hydrates, solvates, salts, and cocrystals, as well as individual phases in mixtures. Moreover, it provides structurally resolved polymorph landscapes that are essential for form selection, regulatory filings, and crystal structure predictions.

Dr. Alex Chen, Co-founder and CEO of Crystal Pharmatech, expressed his enthusiasm for the new equipment, stating, "Five years after launching MicroED on a cryo-EM instrument, we now have a dedicated, automated electron diffractometer in our own laboratory. This instrument promises to be a workhorse for our solid-state research, enabling rapid structure determination with minimal material requirements."

Upcoming Symposium in Boston

In addition to this exciting development, Crystal Pharmatech will showcase the capabilities of MicroED at the Boston Symposium—Executive Networking Reception, scheduled for November 19, 2026. Titled 'First Time Right', the event will feature presentations covering solid-form selection and crystal structure prediction, with key speakers from prominent organizations in the biotech and pharmaceutical sectors.

Attendees will have the opportunity to see MicroED in action and engage with experts including Dr. Gustavo Santiso-Quiñones from ELDICO Scientific AG and executives from Crystal Pharmatech. Registration for the event is available for qualified biotech and pharma R&D professionals.

About Crystal Pharmatech and ELDICO Scientific AG

Founded in 2010, Crystal Pharmatech specializes in various areas of pharmaceutical development, emphasizing solid-state research and formulation innovation. The company has successfully collaborated with over 2,000 clients, including eight of the ten largest pharmaceutical companies globally.

ELDICO Scientific AG, headquartered in Basel, Switzerland, is dedicated to advancing electron diffraction technology for structure analysis in various industries, including pharmaceutical and materials science. Its pioneering ED-1 platform supports detailed MicroED applications for sub-micron crystalline materials, enabling scientists to reach new heights in structural determination and drug development.

As the pharmaceutical sector continues to evolve, advancements like the ELDICO ED-1 will undoubtedly play a vital role in shaping the future of drug discovery and development.

For more information about Crystal Pharmatech's MicroED services or to register for the Boston Symposium, interested parties can visit the company's official website.